

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jul 2026

Effects of Intravitreal Bevacizumab (Avastin) therapy on visual acuity in patients with Proliferative Diabetic Retinopathy

Protocol summary

Summary

Purpose: to evaluate the efficacy and safety of intravitreal bevacizumab in proliferative diabetic retinopathy (PDR) patients. Design: Quasi clinical study Methods: 39 eyes of 26 PDR patients were evaluated. All patients completed 12 weeks of follow-up. Patients were treated with one intravitreal injection of 1.25 mg of bevacizumab. Evaluation consisted of a complete ophthalmologic examination, including Snellen Visual acuity (VA) measurement, ophthalmoscopy and fluorescein angiography (FA). Main outcome measures: changes in VA and FA.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT138903314232N1**
Registration date: **2010-11-26, 1389/09/05**
Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2010-11-26, 1389/09/05

Registrant information

Name

Ebrahim Mikaniki

Name of organization / entity

Babol University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 11 1219 9015

Email address

e.mikaniki@mubabol.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research, Babol University of Medical Sciences

Expected recruitment start date

2007-10-31, 1386/08/09

Expected recruitment end date

2009-10-31, 1388/08/09

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effects of Intravitreal Bevacizumab (Avastin) therapy on visual acuity in patients with Proliferative Diabetic Retinopathy

Public title

Intravitreal Bevacizumab (Avastin) therapy for Proliferative Diabetic Retinopathy

Purpose

Treatment

Inclusion/Exclusion criteria

Patients were not offered treatment if they had uncontrolled hypertension or recent myocardial infarction or cerebral vascular accident.

Age

From **35 years** old to **70 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **39**

Randomization (investigator's opinion)

N/A

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Single

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Babol university of medical sciences

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Postal code

Approval date

2010-10-12, 1389/07/20

Ethics committee reference number

1816

Health conditions studied

1

Description of health condition studied

diabetic retinopathy

ICD-10 code

H36.0

ICD-10 code description

Retinal disorders in diseases classified elsewhere

Primary outcomes

1

Description

Visual Acuity

Timepoint

0, 4, 12 weeks

Method of measurement

complete ophtalmic examination

Secondary outcomes

1

Description

Speed of improvement and durability of visual acuity

Timepoint

4 and 12 weeks after intervention

Method of measurement

ophtalmic examination

Intervention groups

1

Description

One intravitreal injection of 1.25 mg of bevacizumab (Avastin)

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Beheshti Hospital

Full name of responsible person

Dr Mikaniki

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research; Babol university of medical sciences

Full name of responsible person

Vice chancellor for research

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancellor for research; Babol university of medical sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Babol university of medical sciences

Full name of responsible person

Ebrahim Mikaniki

Position

Assistant Professor

Other areas of specialty/work

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Postal code

Phone

+98 11 1219 9015

Fax

Email

dr_emikaniki@yahoo.com

Web page address

Fax

Email

dr_emikaniki@yahoo.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Babol university of medical sciences

Full name of responsible person

Ebrahim Mikaniki

Position

Assistant Professor

Other areas of specialty/work

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Postal code

Phone

+98 11 1219 9015

Fax

Email

dr_emikaniki@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Babol university of medical sciences

Full name of responsible person

Ebrahim Mikaniki

Position

Assistant Professor

Other areas of specialty/work

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Postal code

Phone

+98 11 1219 9015

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty